Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer

NCT00652561 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Non-Small Cell Lung Cancer

Interventions

DRUG: S-1

Sponsor

Taiho Oncology, Inc.

Collaborators

[object Object]
[object Object]